Clinical utility of drug measurement and pharmacokinetics - Therapeutic drug monitoring in psychiatry

European Journal of Clinical Pharmacology

Volumn 64, Issue 2, 2008, Pages 159-166

  Hiemke, Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CITALOPRAM; CLOMETHIAZOLE; CLOZAPINE; CYTOCHROME P450; DEBRISOQUINE; DEXTROMETHORPHAN; FLUOXETINE; FLUVOXAMINE; LOSARTAN; MELPERONE; MEPHENYTOIN; METHADONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; PROGUANIL; REBOXETINE; RISPERIDONE; SPARTEINE; THEOPHYLLINE; TOLBUTAMIDE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN;

AGRANULOCYTOSIS; BLOOD LEVEL; BLOOD TOXICITY; CLINICAL PRACTICE; CONVULSION; DELIRIUM; DRUG METABOLISM; DRUG MONITORING; EDUCATION; HUMAN; METABOLISM; PHARMACOGENETICS; PHYSICIAN; PRIORITY JOURNAL; PSYCHIATRY; REVIEW;

DRUG MONITORING; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MENTAL DISORDERS; PHARMACOLOGY, CLINICAL; PRACTICE GUIDELINES AS TOPIC; PSYCHOTROPIC DRUGS;

EID: 39149104018     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0430-1     Document Type: Review

References (64)

1. Touw DJ, Neef C, Thomson AH, Vinks S (2005) Cost-effectiveness of therapeutic drug monitoring. Ther Drug Monit 27:10-17
2. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G (2004) The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatria 37:243-265
3. Hammer WM, Brodie BB (1967) Application of isotope derivative technique to assay of secondary amines: estimation of desipramine by acetylation with H3-Acetic anhydride. J Pharmacol Exp Ther 157:503-508
4. Åsberg M, Cronholm B, Sjöqvist F, Tuck D (1970) Correlation of subjective side effects with plasma concentrations of nortriptyline. Br Med J 4:18-21
5. Åsberg M, Cronholm B, Sjöqvist F, Tuck D (1971) Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J 3:331-334
6. Curry SH, Davis JM, Janowski DS, Marshall JHL (1970) Factors affecting chlorpromazine plasma levels in psychiatric patients. Arch Gen Psychiatry 22:209-215
7. Alexanderson BH, Evans DA, Sjöqvist S (1969) Steady_state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J 686:764-768
8. Bertilsson L, Mellström B, Sjöqvist F, Märtensson B, Åsberg M (1981) Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet i:560-561
9. Gram LF, Overø KF (1972) Drug inhibition: Inhibitory effects of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J 1:463-465
10. Perry PJ (1987) The relationship between antidepressant response and tricyclic antidepressant plasma concentrations: a retrospective analysis of the literature using logistic regression analysis. Pharmacokinetics 13:381-392
11. Preskorn S, Jerkovich GS (1990) Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 10:88-95
12. Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45:79-91
13. Perry PJ, Miller DD, Arndt SV, Cadoret RJ (1991) Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148:231-235
14. Ulrich S, Wurthmann C, Brosz M, Meyer FP (1989) The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet 34:227-263
15. van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N (1991) Neuroleptic plasma levels. Schizophr Bull 17:197-216
16. Hippius H (1989) The history of clozapine. Psychopharmacology 99:S3-S5
17. Kane JM, Honigfeld G, Singer J, Meltzer H (1988) Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 24:62-67
18. Perry PJ, Miller DD, Arndt SV, Cadoret RJ (1991) Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148:231-235
19. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14:279-281
20. Jerling M, Lindström L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368-374
21. Bengtsson F (2004) Therapeutic drug monitoring of psychotropic drugs TDM "nouveau". Ther Drug Monit 26:145-151
22. Jaquenoud Sirot E, van der Velden JW, Rentsch K, Eap CB, Baumann P (2006) Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Safety 29:735-68
23. Gutteck U, Rentsch KM (2003)Therapeutic drug monitoring of 13 antidepressant and five neuroleptic drugs in serum with liquid chromatography-electrospray ionization mass spectrometry. Clin Chem Lab Med 41:1571-1579
24. Kirchherr H, Kühn-Velten WN (2006) Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. J Chromatogr B 843:100-113
25. Härtter S, Hiemke C (1992) Column switching and high-performance liquid chromatography in the analysis of amitriptyline, nortriptyline and hydroxylated metabolites in human plasma or serum. J Chromatogr 578:273-282
26. Härtter S, Weigmann H, Hiemke C (2000) Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection. J Chromatogr B 740:135-140
27. Saint-Marcoux F, Sauvage FL, Marquet P (2007) Current role of LC-MS in therapeutic drug monitoring. Anal Bioanal Chem 388:1327-1349
28. Farde L, Nordström AL, Wiesel F-A, Pauli S, Halldin C, Sedvall G (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
29. Farde L, Wiesel FA, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71-76
30. 18F]desmethoxyfallypride. J Nucl Med 44:109-116
31. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553-559
32. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA et al (1998) 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155:921-928
33. Medori R, Mannaert E, Gründer G (2006) Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol 16:233-240
34. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161:826-835
35. Nordström A-L, Farde L, Wiesel F-A, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235
36. Talbot PS, Laruelle M (2002) The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 12:503-511
37. Talvik M, Nordstrom AL, Larsen NE, Jucaite A, Cervenka S, Halldin C, Farde L (2004) A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology (Berl) 175:148-153
38. Vernaleken I, Siessmeier T, Buchholz HG, Härtter S, Hiemke C, Stoeter P, Rösch F, Bartenstein P, Gründer G (2004) High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int J Neuropsychopharmacol 7:421-430
39. 11C]raclopride. Neuropsychopharmacology 27:248-259
40. Hiemke C, Dragicevic A, Gründer G, Härtter S, Sachse J, Vernaleken I, Müller MJ Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 26:156-160
41. Lundmark J, Bengtsson F, Nordin C, Reis M, Walinder J (2000) Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiat Scand 101:354-359
42. Müller MJ, Regenbogen B, Härtter S, Eich FX, Hiemke C (2007) Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia J Psychiatr Res 41:673-679
43. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ (2002) World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: acute and continuation treatment of major depressive disorder World J Biol Psychiatry 3:5-43
44. Stassen HH, Angst J, Daniel H, Scharfetter C, Szegedi A (2007) Is there a common resilience mechanism underlying antidepressant drug response. Evidence from 2848 patients. J Clin Psychiatry 68:1105-1205
45. Beasley CM Jr, Stauffer VL, Liu-Seifert H, Taylor CC, Dunayevich E, Davis JM (2007) All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol 27:252-258
46. Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002) Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 59:103-108
47. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-23
48. Chang Y-C, Lane HY, Yang KH, Huang CL (2006) Optimizing early prediction for antipsychotic response in schizophrenia. J Clin Psychopharmacol 26:554-559
49. Leucht S, Busch R, Kissling W, Kane JM (2007) Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 68:352-360
50. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S (2007) Defining "response" in antipsychotic drug trials: recommendation for the use of scale-derived cutoffs. Neuropsychopharmacology (in press)
51. Szegedi A, Müller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O (2003) Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 64:413-420
52. Frank D, Jaehde U, Fuhr U (2007) Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 63:321-333
53. Faber MS, Jetter A, Fuhr U (2005) Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 97:125-1234
54. Streetman DS, Bertino JS Jr, Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187-216
55. Tanaka E, Kurata N, Yasuhara H (2003) How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? J Clin Pharm Ther 28:157-65
56. Nelson DR (2006) Cytochrome P450 nomenclature, 2004. Methods Mol Biol 320:1-10
57. Aranow AB, Hudson JI, Pope HG Jr, Grady TA, Laage TA, Bell IR, Cole JO (1989) Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry 146:911-913
58. Bertschy G, Vandel S, Vandel B, Allers G, Volmat R (1991) Fluvoxamine-tricyclic antidepressant interaction. An accidental finding. Eur J Clin Pharmacol 40:119-120
59. Jerling M, Lindström L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368-374
60. Müller MJ, Dragicevic A, Fric M, Gaertner I, Grasmäder K, Härtter S, Hermann E, Kuss HJ, Laux G, Oehl W, Rao ML, Rollmann N, Weigmann H, Weber-Labonte M, Hiemke C (2003) Therapeutic drug monitoring of tricyclic antidepressants: How does it work under clinical conditions Pharmacopsychiatry 36:98-104
61. Zernig G, Lechner T, Kramer-Reinstadler K, Hinterhuber H, Hiemke C, Saria A (2004) What the clinician still has to be reminded of. Ther Drug Monit 26:582
62. Vuille F, Amey M, Baumann P (1991) Use of plasma level monitoring of antidepressants in clinical practive - Towards an analysis of clinical utility. Pharmacopsychiatry 24:190-195
63. Mann K, Hiemke C, Schmidt LG, Bates DW (2006) Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. Ther Drug Monit 28:83-88
64. Mann K, Hiemke C, Lotz J, Schmidt LG, Lackner KJ, Bates DW (2006) Appropriateness of plasma level determinations for lithium and valproate in routine care of psychiatric inpatients with affective disorders. J Clin Psychopharmacol 26:671-673